Trial Profile
A Phase 1/2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Zigakibart (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Aduro BioTech; Chinook Therapeutics
- 01 Aug 2019 Status changed from active, no longer recruiting to discontinued.
- 04 Jun 2019 Results (Data cut off 7 Dec 2018, n=15) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2019 Results (as of 7 Dec 2018; n=15) assessing tolerability of 50-1350 mg dose of BION-1301 and reduces serum levels of fAPRIL in patients with multiple myeloma, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.